C
Cytek Biosciences, Inc. (CTKB)
NMS – Real Time Price. Currency in USD
4.04
-0.08 (-1.94%)
At close: May 12, 2026, 4:00 PM EDT
4.28
+0.24 (5.94%)
After-hours: May 12, 2026, 7:12 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
4.04
-0.08 (-1.94%)
At close: May 12, 2026, 4:00 PM EDT
4.28
+0.24 (5.94%)
After-hours: May 12, 2026, 7:12 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 5.04 | 3.40 | 10 | |
| Quick ratio | 4.42 | 2.52 | 10 | |
| Debt to Equity | 0.10 | 1.11 | 9.0 | |
| Debt to Assets | 0.07 | 1.58 | 9.0 | |
| Interest coverage | N/A | 4.33 | 1.0 | |
| Weighted average score | 7.8 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 164M | 193M | 200M | 201M | 201M |
| Gross Profit | 102M | 109M | 111M | 104M | 104M |
| Operating Income | -1M | -26M | -23M | -40M | -40M |
| Net Income | 3M | -12M | -6M | -67M | -67M |
| EBITDA | 4M | -17M | -13M | -28M | -29M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 6.6 | -58.33 | 3.0 |
| Next quarter | 5.49 | -1131 | 3.0 |
| Current year | 3.37 | 51.44 | 7.0 |
| Next year | 6.95 | 39.6 | 7.5 |
| Weighted average score | 5.1 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 18.83 | -704.59 | -8189.45 | 61.1 | 5.3 |
| Y/Y | 8.12 | -557.07 | -381.36 | -260.64 | 2.3 |
| 3y average | 7.35 | -508.8 | 28.54 | 1105.07 | 6.5 |
| 5y average | 17.61 | -125.47 | 1.96 | -1029.11 | 3.5 |
| Weighted average score | 4.4 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $90.9M significantly exceed its total debt $33.0M, ensuring strong financial flexibility
Total current assets $392.0M exceed Total current liabilities $77.8M, highlighting excellent liquidity
Debt-to-equity ratio (0.1) is well below the industry average (1.1), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$1.8M limits the company's ability to reinvest or pay down debt